scholarly journals Long-term results of the effect of intravitreal ranibizumab on the retinal arteriolar diameter in patients with neovascular age-related macular degeneration

2013 ◽  
Vol 91 (3) ◽  
pp. e184-e190 ◽  
Author(s):  
Efstratios Mendrinos ◽  
Georgios Mangioris ◽  
Domniki N. Papadopoulou ◽  
Guy Donati ◽  
Constantin J. Pournaras
Keyword(s):  
Macular Degeneration ◽  
Age Related Macular Degeneration ◽  
Long Term Results ◽  
Intravitreal Ranibizumab ◽  
Age Related ◽  
Arteriolar Diameter ◽  
Retinal Arteriolar ◽  
Retinal Arteriolar Diameter

Long-Term Results of Radiotherapy for Age-Related Macular Degeneration

2001 ◽  
pp. 103-109
Author(s):  
G.J. Bergink ◽  
C.B. Hoyng ◽  
R.W.M. van der Maazen ◽  
J.R. Vingerling ◽  
W.A.J. van Daal ◽  
...  
Keyword(s):  
Macular Degeneration ◽  
Age Related Macular Degeneration ◽  
Long Term Results ◽  
Age Related

scholarly journals Long term intravitreal ranibizumab treatment for exsudative age-related macular degeneration

2013 ◽  
Vol 154 (45) ◽  
pp. 1790-1797 ◽  
Author(s):  
Regina Lukács ◽  
Miklós Resch ◽  
András Papp ◽  
Antal Szabó ◽  
Ágnes Borbándy ◽  
...  
Keyword(s):  
Macular Degeneration ◽  
Retinal Thickness ◽  
Age Related Macular Degeneration ◽  
Central Retinal Thickness ◽  
First Year ◽  
Intravitreal Ranibizumab ◽  
Age Related ◽  
Pro Re Nata ◽  
Ranibizumab Treatment

Introduction: The results of intravitreal ranibizumab treatment for exsudative age-related macular degeneration have been favourable until this time. Aim: To evaluate the two-year functional and anatomic results of intravitreal ranibizumab treatment. Method: 46 patients (age: 75±9.1 years) were included in a prospective single center study. Treatment regimen was the following: monthly 0.5 mg ranibizumab was administered in the first 3 months, and later as required (pro re nata). The change of best corrected visual acuity and central retinal thickness was followed. Results: The visus change at the end of the follow-up time was not statistically significant compared to baseline (p = 0.760) and the at the end of the first year (p = 0.154). Central retinal thickness decreased significantly compared to baseline (p = 0.000001), but the change was not statistically significant compared to the end of the first year (p = 0.875). Conclusions: Patients with neovascular macular degeneration treated with intravitreal ranibizumab using pro re nata regimen have stable visus for long term, and the exsudation could be reduced efficiently. Orv. Hetil., 154(45), 1790–1797.

Long-Term Results of Pro Re Nata Regimen of Aflibercept Treatment in Persistent Neovascular Age-Related Macular Degeneration

2016 ◽  
Vol 170 ◽  
pp. 246-247 ◽  
Author(s):  
Ramesh Venkatesh ◽  
Prachi Abhishek Dave ◽  
Shalini Singh ◽  
Prachi Gurav ◽  
Gaganjeet Gujral
Keyword(s):  
Macular Degeneration ◽  
Age Related Macular Degeneration ◽  
Long Term Results ◽  
Age Related ◽  
Pro Re Nata
Sign in / Sign up

Export Citation Format

Share Document